Who owns Stoke Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of STOK from SEC Form 13F filings across 185 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 185 institutions disclosed 73.7M shares of Stoke Therapeutics, Inc. worth $1.92B — about 107.8% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
185
13F holders
$1.92B
value, 2026 filers
107.8%
of shares outstanding (73.7M sh)
18
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of STOK's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.3M | $165.0M | 0.0% | 9.3% | +8.0% |
| 2 | RTW INVESTMENTS, LP | 5.6M | $146.2M | 1.5% | 8.2% | 0.0% |
| 3 | FMR LLC | 5.0M | $130.0M | 0.0% | 7.3% | -5.9% |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 4.7M | $121.7M | 0.0% | 6.8% | +33.0% |
| 5 | Lynx1 Capital Management LP | 3.9M | $101.3M | 15.7% | 5.7% | -3.5% |
| 6 | Redmile Group, LLC | 3.9M | $100.6M | 7.4% | 5.7% | -1.9% |
| 7 | BVF INC/IL | 3.6M | $93.8M | 3.1% | 5.3% | +41.7% |
| 8 | MORGAN STANLEY | 3.2M | $83.5M | 0.0% | 4.7% | -7.0% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2.7M | $71.1M | 0.0% | 4% | +5.7% |
| 10 | STATE STREET CORP | 2.6M | $68.0M | 0.0% | 3.8% | -8.2% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.4M | $63.1M | 0.0% | 3.6% | -8.8% |
| 12 | T. Rowe Price Investment Management, Inc. | 2.1M | $53.7M | 0.0% | 3% | -14.4% |
| 13 | Siren, L.L.C. | 2.0M | $51.9M | 1.2% | 2.9% | 0.0% |
| 14 | Janus Henderson Group Ltd.NEW | 2.0M | $51.3M | 0.0% | 2.9% | new |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.8M | $47.4M | 0.7% | 2.7% | 0.0% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.6M | $40.8M | 0.0% | 2.3% | +2.9% |
| 17 | BAKER BROS. ADVISORS LP | 1.3M | $34.2M | 0.2% | 1.9% | -60.6% |
| 18 | Assenagon Asset Management S.A. | 1.2M | $30.7M | 0.0% | 1.7% | +4.6% |
| 19 | GOLDMAN SACHS GROUP INC | 1.0M | $26.2M | 0.0% | 1.5% | +75.5% |
| 20 | MPM BIOIMPACT LLC | 925,133 | $24.1M | 1.8% | 1.4% | +27.9% |
| 21 | DIMENSIONAL FUND ADVISORS LP | 924,342 | $24.0M | 0.0% | 1.4% | -8.8% |
| 22 | EcoR1 Capital, LLC | 835,000 | $21.7M | 1.0% | 1.2% | +13.6% |
| 23 | Polar Capital Holdings Plc | 831,128 | $21.6M | 0.1% | 1.2% | -0.3% |
| 24 | Troluce Capital Advisors LLC | 806,108 | $21.0M | 1.9% | 1.2% | +62.4% |
| 25 | Opaleye Management Inc. | 692,181 | $18.0M | 2.0% | 1% | -1.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.